Are you a physician or nurse?

Yes No
The UroLift System Icon

The UroLift® System

An earlier alternative to medical therapy that provides rapid relief and recovery of BPH symptoms.1,3,4 The UroLift® System is minimally invasive and offers better symptom relief than medication4 with a lower risk profile than TURP.2

Learn More About the Procedure

Clinical Results Icon

Results

The UroLift System is supported by extensive clinical experience in controlled studies; large multi-centre studies; small studies; retrospective registry and peer-reviewed publications. 

Explore the Results

Publications

Publications

View the spectrum of UroLift System clinical results and data:

  • Meta-Analyses
  • Real World Experience Studies
  • Clinical Studies 
  • International Publications
  • Reviews

View More Publications

IFU Icon

Instructions for Use

Download the UroLift System Instructions for Use document to learn more about:

  • Product Description
  • Device Positioning (Lateral and Median Lobes)
  • Implant Deployment
  • MRI Safety Information

See Instructions for Use

Source Information

  1. Shore, Can J Urol 2014
  2. Sonksen, Eur Urol 2015
  3. Roehrborn, J Urology 2013
  4. Roehrborn, Can J Urol, 2017

INFORMATION FOR PHYSICIANS ABOUT THE UROLIFT® SYSTEM

The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years or older. The UroLift implants are permanent and can be delivered during an outpatient procedure, relieving prostate obstruction without heating, cutting, destructing, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.1 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*2-4 Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.5 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines.
 
Contraindicated in men with a prostate volume greater than 100cc or a urinary tract infection.

 

Warning: This device contains stainless steel and nitinol, an alloy of nickel and titanium. Persons with allergic reactions to these metals may suffer an allergic reaction to this implant. Prior to implantation, patients should be counseled on the materials contained in the device, as well as potential for allergy/hypersensitivity to these materials.

Individual results may vary. For full information, please consult the Instructions for Use (IFU)

*No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.

  1. Rukstalis, Prostate Cancer and Prostatic Dis 2018
  2. Roehrborn, Can J Urol 2017
  3. AUA BPH Guidelines 2003, 2020
  4. McVary, J Sex Med 2016
  5. Roehrborn, J Urology 2013

 

Teleflex, BPH Relief In Sight and UroLift are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. ©2023 Teleflex Incorporated. All rights reserved. Revised: 02/2023. MC-008657 LA EN

Teleflex Medical Brasil Ltda
Rua Alexandre Dumas, 2100/132 - Chacara Santo Antonio
São Paulo/SP - CEP 04717-913